Zevra Therapeutics’ Miplyffa approved for Niemann-Pick type C. Read why ZVRA stock presents both potential and risks for long ...
Objective To determine whether any children in the UK had variant Creutzfeldt-Jakob disease (vCJD). Design This active ...
Celiprolol is our Phase 3 investigational clinical candidate, for the treatment of vascular Ehlers-Danlos Syndrome or VEDS ... validated endpoint, the Niemann Pick Disease Type C Clinical Severity ...
MIPLYFFA, Zevra’s treatment for Niemann-Pick Disease Type C (NPC), has been the cornerstone ... KP1077 for idiopathic hypersomnia and Celiprolol for vascular Ehlers-Danlos syndrome (VEDS). KP1077 has ...
In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome ... that more than half of individuals with Niemann-Pick disease, type C1 (NPC1) who were tested ...
Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B HST32 2 ... for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and ...
The first is VTS-270 is in phase 3 development for Niemann-Pick Type C (NPC), a rare ... constipation linked to irritable bowel syndrome and chronic opioid use. Analysts say the company will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback